metabolic research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-28. Numbers and descriptions here follow the published literature rather than marketing material.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Macimorelin (INN) – or Macrilen (trade name) – is a drug that was developed by Aeterna Zentaris for use in the diagnosis of adult growth hormone deficiency. Macimorelin acetate, the salt formulation, is a synthetic growth hormone secretagogue receptor agonist. It is a growth hormone secretagogue receptor (ghrelin receptor) agonist, causing release of growth hormone from the pituitary gland. Macimorelin acetate is described chemically as D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-acetate. Macimorelin (Macrilen) was invented and first synthesized at University of Montpellier, Centre National de la Recherche Scientitifique (CNRS), France. This transpired from a long-lasting research collaboration with Aeterna Zentaris. Aeterna Zentaris later in-licensed macimorelin as a development candidate from the CNRS and proceeded with the pre-clinical and clinical development of the compound. As of January 2014, it was in Phase III clinical trials. The phase III trial for growth hormone deficiency is expected to be complete in December 2016. As of December 2017, it was FDA-approved as a method to diagnose growth hormone deficiency. Traditionally, growth hormone deficiency was diagnosed via means of insulin tolerance test (IST) or glucagon stimulation test (GST). These two means are done parenterally, whereas Macrilen boasts an oral formulation for ease of administration for patients and providers. In November 2018 Novo Nordisk would acquire the rights to Macrilen, at a cost of $145 million.
== Pathophysiology == Muscle atrophy occurs due to an imbalance between the normal balance between protein synthesis and protein degradation. This involves complex cell signalling that is incompletely understood and muscle atrophy is likely the result of multiple contributing mechanisms. Mitochondrial function is crucial to skeletal muscle health and detrimental changes at the level of the mitochondria may contribute to muscle atrophy. A decline in mitochondrial density as well as quality is consistently seen in muscle atrophy due to disuse. The ATP-dependent ubiquitin/proteasome pathway is one mechanism by which proteins are degraded in muscle. This involves specific proteins being tagged for destruction by a small peptide called ubiquitin which allows recognition by the proteasome to degrade the protein.
1993/2131) Courts and Legal Services Act 1990 (Commencement No. 9) Order 1993 (S.I. 1993/2132) Rules of the Supreme Court (Amendment) 1993 (S.I. 1993/2133) Leasehold Reform, Housing and Urban Development Act 1993 (Commencement and Transitional Provisions No. 1) Order 1993 (S.I. 1993/2134) Edinburgh Assay Office (Amendment) Order 1993 (S.I. 1993/2135) County Court (Amendment No. 2) Rules 1993 (S.I. 1993/2150) Combined Probation Areas (Hertfordshire) Order 1993 (S.I. 1993/2151) Manchester, Liverpool Road (Castlefield Properties Limited) Light Railway Order 1993 (S.I. 1993/2153) East Kent Light Railway Order 1993 (S.I. 1993/2154) Mental Health (Nurses) Amendment Order 1993 (S.I. 1993/2155) Mental Health (Hospital, Guardianship and Consent to Treatment) Amendment Regulations 1993 (S.I. 1993/2156) Leasehold Reform, Housing and Urban Development Act 1993 (Commencement No. 2) (Scotland) Order 1993 (S.I. 1993/2163) Housing (Preservation of Right to Buy) (Scotland) Regulations 1993 (S.I. 1993/2164) Employment Protection (Continuity of Employment) Regulations 1993 (S.I. 1993/2165) Controlled Drugs (Substances Useful for Manufacture) (Intra–Community Trade) Regulations 1993 (S.I. 1993/2166) Tobacco Products (Amendment) Regulations 1993 (S.I. 1993/2167) A45/A452 Trunk Roads (Stonebridge Grade Separation) Order 1993 (S.I. 1993/2168) Education (Further Education Institutions Information) (Wales) Regulations 1993 (S.I. 1993/2169) A45 Trunk Road (Middle Bickenhill to Stonebridge) (De-Trunking) Order 1993 (S.I.
Sources: en.wikipedia.org
Lastly, the sixth variant (K5R_I10H_F12W) was developed by combining the amino acid substitutions of the first and second variants. Moreover, researchers from the Clemens-Schöpf Institute of Organic Chemistry and Biochemistry and Helmholtz-Institute for Pharmaceutical Research Saarland, developed potent synthetic human matriptase-1 inhibitors based on a different SFTI-1 variant, SDMI-1. SFTI-1 derived matriptase inhibitor-1 (SDMI-1) was previously developed by replacing residue 10 of SFTI-1 (isoleucine, I) with arginine (R) and residue 12 (phenylalanine, F) with histidine (H). Further modifications of SDMI-1 resulted in synthetic matriptase-1 inhibitors with improved inhibitory activity, matriptase binding, and inhibition potency. The SDMI-1 variant that resulted in enhanced inhibitory activity was developed by replacing residue 1 of SDMI-1 (glycine, G) with lysine (K) and by keeping it as a monocyclic structure. The SDMI-1 variant that resulted in improved matriptase binding was created by using the same amino acid substitutions of the previously mentioned SDMI-1 variant and by attaching a bulky fluorescein moiety to the side chain of lysine. Lastly, the SDMI-1 variant that had enhanced inhibition potency was developed by applying the same amino acid substitutions of the previous variants, cleaving the proline-aspartic acid sequence found at the C-terminus (PD-OH), and by making it a bicyclic compound via tail-to-side-chain cyclization.
After the unbound probes are washed away, the Western blot is ready for detection of the probes that are labeled and bound to the protein of interest. In practical terms, not all Westerns reveal protein only at one band in a membrane. Size approximations are taken by comparing the stained bands to that of the marker or ladder loaded during electrophoresis. The process is commonly repeated for a structural protein, such as actin or tubulin, that should not change between samples. The amount of target protein is normalized to the structural protein to control between groups. A superior strategy is the normalization to the total protein visualized with trichloroethanol or epicocconone. This practice ensures correction for the amount of total protein on the membrane in case of errors or incomplete transfers. (see Western blot normalization)
In 1893, Prof. Niels Ryberg Finsen (1860–1904) began to treat lupus vulgaris, a tubercular condition of the skin, in the direct mode with heat-filtered light from a carbon arc lamp. He established the Phototherapy treatment at the Whitechapel Hospital in London, which had a Light Department in the first decade of the 20th century. His activity had royal patronage, and Niels Ryberg Finsen received the Nobel Prize in 1903. In 1894, neurologist and psychiatrist Edward Flatau published a human brain atlas, "Atlas of the Human Brain and the Course of the Nerve-Fibres," which consisted of long-exposure photographs of fresh brain sections. It contained an overview of the knowledge of the time on the fibre pathways in the central nervous system. In 1924, the German psychiatrist Hans Berger attached electrodes to the scalp and detected small currents in the brain. In the 1940s, the US War Department investigated the use of electrical stimulation and used so-called "galvanic exercises" on the atrophied hands of patients with ulnar nerve damage from wound surgery, not only to slow and prevent atrophy, but also to restore muscle mass and strength. In the mid-20th century, the scientific study of neuromodulation in humans expanded significantly. Neurologist Professor Spiegel and neurosurgeon Professor Weissys of Temple University presented a stereotactic device to perform "ablation procedures" in humans; in 1947, "intraoperative electrical stimulation" was introduced to test the brain's target zone before surgery.
Between 790 and 800, the first Scandinavian Viking raiders targeted the coasts of northern Gaul. Several coastal areas were lost during the reign of Louis the Pious (814–840). The Seine became the main route by which they entered the Kingdom of France. In 820, the first Viking attack sailed up the river; these raids became more frequent primarily in summer, while the Vikings initially wintered in Scandinavia. In the course of the 10th century, the initially destructive incursions of Norse war bands penetrated further into the rivers of France, and evolved into more permanent encampments that included local French women and personal property. From 885 to 886, Odo of Paris (Eudes de Paris) succeeded in defending Paris against Viking raiders by fighting skill, fortification of Paris and tactical shrewdness. Before Rollo's arrival, Normandy's populations did not differ from Picardy or Île-de-France, which were considered Frankish. Earlier Viking settlers had begun arriving in the 880s, but were divided between colonies in the east (Roumois and Pays de Caux around the lower Seine valley) and in the west in the Cotentin Peninsula, and were separated by traditional pagii, where the population remained about the same with almost no foreign settlers. Rollo's contingents from Scandinavia who raided and ultimately settled Normandy and other parts of the European Atlantic coast included Danes, Norwegians, Norse–Gaels, Orkney Vikings, possibly Swedes, and Anglo-Danes from the English Danelaw territory which earlier came under Norse control in the late 9th century.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.